Title
Date
- Korea Eases Biosimilar Phase 3 and Animal Testing Requirements: What MFDS’s July 2026 Rule Change Means for Sponsors
- Korean Biotech’s China Pivot: What the Rush to Chinese Clinical Trials Means for Sponsors Evaluating Korea
- The Obesity Drug Race Just Got Harder to Win: What CagriSema and Retatrutide Mean for Sponsors Evaluating Korea
- Decentralized Clinical Trials Are Going Mainstream: Is Korea Ready for the Shift?
- MFDS’s AI Review Rollout and Medical Device Negative-List Reform: What They Actually Mean for Korea Clinical Trial Timelines in 2026
- The First In Vivo CRISPR Therapy Just Cleared Phase 3: What Lonvo-z Means for Gene-Editing Trials in Korea
- Running Bispecific Antibody and T-Cell Engager Trials in Korea: A Sponsor’s Regulatory and Operational Playbook
- FDA and EMA’s 2026 AI and Bayesian Guidance: What the New Regulatory Convergence Means for Clinical Trial Design in Korea